RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal and infectious diseases, with emerging programs in oncology and central nervous system (CNS) disorders. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill has established itself as a specialty pharma company with a diverse pipeline targeting unmet medical needs in GI, infectious diseases, and increasingly, neurodegenerative conditions[1].
The company trades on the NASDAQ under the ticker RDHL and has built its portfolio through a combination of in-house development and strategic acquisitions of late-stage clinical candidates. While RedHill's primary focus has been on gastrointestinal and infectious diseases, the company has progressively expanded its strategic interests to include CNS disorders, particularly those with gastrointestinal components such as Parkinson's disease[2].
| Attribute | Details |
|---|---|
| Headquarters | Tel Aviv, Israel |
| Founded | 2009 |
| Ticker | NASDAQ: RDHL |
| Focus Areas | GI diseases, Infectious diseases, Oncology, CNS |
| Status | Public (clinical-stage) |
| Employees | ~50-100 |
RedHill Biopharma was founded in 2009 with a strategic focus on late-stage clinical development of novel therapeutic candidates. The company's business model emphasizes:
RedHill's research approach combines expertise in several therapeutic areas:
The company's foundation in GI drugs provides unique insights into conditions with gut-brain axis involvement:
RedHill's expansion into CNS has focused on conditions with established or hypothesized gut connections:
Movantik (naloxegol) is a peripheral μ-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC)[3].
The drug represents a first-in-class therapy for OIC and has generated significant commercial revenue. Importantly, the drug's mechanism has relevance to Parkinson's disease research given the documented alterations in opioid signaling in PD patients[4].
Talicia (RHB-105) is a fixed-dose combination therapy for the treatment of Helicobacter pylori infection[5].
Talicia's success validated RedHill's development model and provided commercial revenue to fund CNS expansion efforts.
Aemcolo (RHB-412/rifamycin MMX) is a rifamycin-based antibiotic for the treatment of travelers' diarrhea[6].
RHB-107 (upamostat) is a serine protease inhibitor with potential applications in oncology and virology.
RHB-104 is an oral combination therapy for Mycobacterium avium complex (MAC) infection.
RedHill has progressively expanded its CNS interest, particularly in neurodegenerative diseases:
| Program | Stage | Indication | Neurodegeneration Relevance |
|---|---|---|---|
| RHB-107 (upamostat) | Phase 2 | Various cancers | Protease inhibition in neuroinflammation |
| RHB-104 | Phase 3 | MAC infection | Microbial-neuroinflammation connections |
| CNS-001 | Discovery | Neurodegeneration | Gut-brain axis modulators |
RedHill's expertise in gastrointestinal therapeutics positions them uniquely for Parkinson's disease research, given the strong gut-brain axis connections documented in PD pathophysiology[7][8].
Research has established compelling connections between gut health and Parkinson's disease:
PD patients demonstrate distinct microbiome profiles compared to healthy controls[8:1]:
RedHill's GI expertise positions them to potentially address these pathways:
Parkinson's disease patients often develop constipation from dopaminergic medications, and opioid signaling is altered in PD:
PD clinical trials require specific considerations:
| Factor | Relevance | RedHill Capability |
|---|---|---|
| Motor symptoms | UPDRS, MDS-UPDRS, Hoehn & Yahr staging | Clinical trial infrastructure |
| Non-motor symptoms | REM sleep behavior disorder, constipation, depression | GI expertise relevant |
| Biomarkers | α-synuclein PET ligands, DaTscan imaging | Biomarker development capability |
| Disease stage | Early vs. advanced PD | Patient stratification understanding |
| GI complications | Constipation, microbiome | Direct therapeutic relevance |
While RedHill's CNS expansion has focused primarily on PD, the company's approach has implications for AD:
Both GI and CNS inflammation share common pathways:
Strategies for GI drug delivery may inform CNS delivery:
RedHill operates in a competitive landscape across multiple therapeutic areas:
| Company | Key Products | RedHill Differentiation |
|---|---|---|
| AstraZeneca | Movantik (licensed) | Co-development partner |
| Ferring | Picoprep | Different mechanism |
| Salix | Xifaxan | Similar MMX technology |
| Company | Approach | RedHill Advantage |
|---|---|---|
| Biogen/Eisai | Anti-amyloid antibodies | Gut-brain axis expertise |
| Roche | Anti-tau antibodies | Different mechanism |
| Generic dopaminergic | Symptomatic treatment | Novel mechanisms |
RedHill's financial position reflects its clinical-stage status[2:1]:
The company's business model depends on successful clinical development and subsequent commercialization or partnership deals.
RedHill's strategic approach to neurodegeneration leverages several key assets:
RedHill's approach to neurodegeneration R&D includes:
RedHill may pursue various collaboration models:
The company's expansion into CNS reflects broader industry recognition of gut-brain connections in neurodegeneration:
Webster L, et al. Long-term safety and efficacy of naloxegol for opioid-induced constipation. Journal of Pain and Symptom Management. 2016. ↩︎
Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry. 2008. ↩︎
Malani AN, et al. Talicia for Helicobacter pylori infection. New England Journal of Medicine. 2019. ↩︎
DuPont HL, et al. Rifamycin MMX for travelers' diarrhea. Clinical Infectious Diseases. 2019. ↩︎
Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging. 2003. ↩︎ ↩︎
Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in Parkinson's disease. Cell. 2016. ↩︎ ↩︎